LII shares fell -14.79% during regular trading after reporting Q2 2026 results before the market opened, erasing months of gains in a single session. Q2 revenue of $1.55B narrowly missed the $1.56B consensus estimate, while GAAP EPS of $7.72 was roughly in line with the $7.73 analyst consensus.

BSX dropped -5.88% during premarket and early regular trading after reporting Q2 2026 results that beat estimates but included a sharp guidance cut. Q2 earnings topped consensus: adjusted EPS of $0.86 vs. $0.83 expected, and revenue of $5.44 billion vs. $5.36 billion, driven by 7.5% year-over-year sales growth.

VRT tumbled approximately -10.1% during regular trading Wednesday after its Q2 2026 earnings report beat on profit but missed on revenue, triggering a sharp selloff. Adjusted EPS of $1.52 surpassed the $1.42 consensus by +6.4%, yet revenue of $3.27B fell roughly -3.4% short of the $3.38B analyst estimate, overshadowing the bottom-line beat.

Profit surge: Underlying earnings jumped 43% year-over-year to $6.85 billion for the half year ended June 30, 2026, the highest half-year profit in four years. Revenue growth: Consolidated sales revenue rose 15% to $31.03 billion, supported by higher commodity prices and increased production volumes across key commodities.

Revenue beat: GSK posted second-quarter turnover of £8.41 billion, exceeding the analyst consensus of £8.24 billion and rising 5% at constant exchange rates (CER). Profit outperformance: Core operating profit reached £2.80 billion, ahead of the £2.68 billion consensus, while core earnings per share (EPS) of 50.5 pence comfortably beat the 47.1 pence forecast.

Core sales rose 17% year over year to $4.74 billion, surpassing the consensus estimate of approximately $4.62 billion. Core earnings per share (EPS) climbed 30% to $0.78, beating analyst expectations of $0.75 to $0.76.

Revenue topped expectations: GAAP revenue reached $4.15 billion, up 10% year-over-year, exceeding the analyst consensus of approximately $4.12 billion. Adjusted EPS beat estimates: Adjusted earnings per share came in at $4.83, a 23% increase from $3.92 a year ago, surpassing the FactSet consensus of $4.81.

Visa reported fiscal third-quarter 2026 net revenue of $11.63 billion, up 14% year-over-year, exceeding the consensus estimate of approximately $11.38 billion. Adjusted earnings per share (EPS) came in at $3.32, beating analyst expectations of $3.23 and marking an 11% increase from the prior-year period.

Revenue significantly exceeded expectations: Seagate posted fiscal Q4 2026 revenue of $3.63 billion, comfortably beating the FactSet consensus estimate of $3.5 billion and surging 49% year-over-year. Non-GAAP earnings per share (EPS) crushed estimates: Adjusted EPS came in at $5.71, well above the $5.10 analyst consensus and up 120% from $2.59 in the prior-year quarter.

Revenue beat expectations: Boeing reported Q2 revenue of $24.6 billion, exceeding the Bloomberg consensus estimate of $24.26 billion and rising 8% year-over-year. Loss wider than anticipated: Core (non-GAAP) loss per share came in at $0.76, well above the $0.28 consensus loss estimate, driven by ongoing profitability challenges.

Revenue beat: KLA posted Q4 FY2026 revenue of $3.66 billion, exceeding the consensus estimate of $3.61 billion and landing above the midpoint of its own guidance range. Earnings outperformance: Non-GAAP diluted EPS (earnings per share) came in at $1.05, surpassing analyst expectations of $1.00 per share and hitting the upper end of company guidance.

Coca-Cola exceeded Wall Street estimates in the second quarter of 2026, reporting adjusted earnings of $0.97 per share versus the $0.93 consensus and net revenues of $13.38 billion against expectations of approximately $13.16 billion. Global unit case volume grew 5% , marking a meaningful acceleration driven by FIFA World Cup marketing activation, favorable weather in select markets, and continued strength in Coca-Cola Zero Sugar, which surged 16%.

Microsoft shares have moved approximately +2.3% over the last 30 days, recovering from a June low near $349 but remaining well below the 50-day and 200-day moving averages. The stock is down roughly 21% year-to-date, making it the second-worst performer among the "Magnificent Seven" in 2026, as AI infrastructure spending fears dominate sentiment.

Micron Technology shares fell approximately 28% over the past 30 days, dropping from $1,145.28 on June 29 to $820.53 on July 28, 2026. The sell-off was driven by a sector-wide retreat from AI-linked memory stocks, renewed fears of Chinese competition after ChangXin Memory Technologies' IPO, and growing skepticism around hyperscaler AI spending.

Robinhood (HOOD) shares have pulled back approximately 8.9% over the past 30 days, trading near $92.76 as of late July 2026, ahead of the company's highly anticipated Q2 earnings report. The launch of Robinhood Chain — an Ethereum Layer-2 blockchain — has driven rapid adoption, surpassing 328,000 real-world asset holders and attracting over $325 million in total value locked within its first month.

GLW plunged -15.08% during Tuesday's regular session after reporting Q2 results that beat estimates but issuing Q3 revenue guidance that fell slightly short of elevated Street expectations. Q2 core EPS of $0.78 on $4.74B in core sales topped consensus, yet Q3 revenue guidance of $4.9B–$5.0B (midpoint $4.95B) came in just below the ~$5B analysts had penciled in.

SHAZ plunged -18.47% during regular trading hours on Tuesday, dropping from a prior close of $58.79 to $47.93, extending a multi-week rout that has erased more than half its value since early July peaks near $97. The selloff follows yesterday's -9.40% decline and reflects mounting investor anxiety ahead of the company's Q2 2026 earnings announcement, after Q1 results missed estimates with an EPS of -$1.43 versus -$0.89 expected and negligible revenue of just $1.54 million TTM.

CVLT shares plunged -15.94% during Tuesday's regular session, despite reporting fiscal Q1 (June quarter) results that beat on both adjusted EPS ($1.42 vs. $1.16 consensus) and revenue ($314.1M vs. $310.5M consensus). The sell-off was triggered by a significant miss on annual recurring revenue (ARR), which came in at $1.05 billion versus the $1.15 billion analysts had projected, while billings declined -5.9% year-over-year.

SANM plunged -19.52% during regular trading on Tuesday after reporting Q3 FY2026 results that beat on both EPS ($3.31 vs. $2.79 consensus) and revenue ($3.46B vs. $3.40B), yet disappointed with forward guidance. The selloff was driven by Q4 revenue guidance of $3.3B–$3.6B (midpoint $3.45B), which came in below the $3.52B analyst consensus, alongside a lower ZT Systems Q4 revenue outlook of $0.8B–$1.0B due to legacy program timing shifts.

REPL crashed -32.1% during regular trading on Tuesday after FDA briefing documents cast serious doubt on the efficacy of its lead skin cancer drug candidate RP1 (vusolimogene oderparepvec). The FDA reviewers stated the single-arm IGNYTE trial design makes it impossible to determine whether RP1 contributed any meaningful benefit beyond Bristol Myers Squibb's Opdivo alone, calling the overall survival data "not interpretable."